Repligen | RGEN - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Agilent USD 7.12B 214M 2026-03
Align Technology USD 4.15B 100.27M 2026-03
Bio Techne USD 2.09B 74.32M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Bruker USD 2.46B 35.9M 2025-12
Charles River Laboratories USD 2.9B 265.94M 2026-03
Danaher USD 52.95B 415M 2026-03
Dentsply International USD 1.32B 21M 2026-03
General Electric Aerospace USD 18.06B 841M 2026-03
Henry Schein USD 3.27B 21M 2026-03
Illumina USD 2.68B 47M 2026-03
IQVIA Holdings USD 6.22B 282M 2026-03
Mettler Toledo International USD -41.88M 18.25M 2026-03
Myriad Genetics USD 337.4M 30.6M 2026-03
OraSure Technologies USD 313.32M 27.5M 2026-03
Pacific Biosciences Of California USD 2.37M 2.98M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Repligen USD 2.11B 666K 2026-03
Revvity USD 7.25B 125.54M 2025-12
Standard Biotools USD 561.12M 136.83M 2026-03
Thermo Fisher Scientific USD 51.93B 1.6B 2026-03
Waters USD 2.56B 230.55M 2025-12
West Pharmaceutical Services USD 2.99B 185.6M 2026-03